Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for NeuroPace Inc. (NPCE:NASDAQ), powered by AI.
NeuroPace Inc. is currently trading at $15.02. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for NeuroPace Inc. on Alpha Lenz.
View NeuroPace Inc.'s valuation metrics on Alpha Lenz.
“NeuroPace Inc.'s ROE is -158.7%. Explore profitability and growth together.”
Ask for details →NeuroPace Inc. is a medical technology company specializing in the development of innovative neurostimulation solutions for neurological disorders. The company is primarily known for its RNS System, a groundbreaking implantable device designed to reduce the frequency and severity of epileptic seizures. The system continuously monitors brain activity and delivers targeted electrical stimulation to help normalize disruptive brainwave patterns. This technology serves as a critical option for patients with refractory epilepsy who do not respond to traditional medication treatment. NeuroPace’s approach directly impacts the healthcare sector, especially the neurology and medical devices markets, by providing a novel alternative to managing severe neurological conditions. Its contributions emphasize advancements in patient-tailored therapy solutions and underscore the growing role of precision medicine in healthcare. Founded with the mission to transform epilepsy treatment, NeuroPace Inc. embodies the synergy of cutting-edge science and patient care, positioning itself as an influential player in the medical technology industry.
“NeuroPace Inc.'s ROE is -158.7%. Explore profitability and growth together.”
Ask for details →NeuroPace Inc. (ticker: NPCE) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 209 employees.
The current price is $15.02 with a P/E ratio of -x and P/B of -x.
ROE is -158.74% and operating margin is -16.34%. Annual revenue is $100M.